Business in 2006

Pressure is mounting on US regulators to create an approval track for generic versions of biotechnology drugs. Meredith Wadman reports.

The bid by Airbus to challenge the Boeing 747's dominance of the market faces an aerodynamic obstacle. Ned Stafford reports.

In future, hospitals should be able to sequence patient DNA swiftly and cheaply. Rex Dalton reports on the firms bringing that day closer.

Lack of regulation and risk assessment could hamper the nanotechnology sector. Virginia Gewin reports.

Pharmaceuticals made in genetically modified animals have been poised to take off for years. Heidi Ledford investigates the reality.

Women academics are less likely than men to take out patents. Emma Marris investigates the reasons why.

Biotechnology companies come in many shapes and sizes, but, say two economists, the ones with the widest spread of skills in their teams stand the best chances of success. Aaron Bouchie reports.

Young blood is taking the helm at the world's biggest drug firm. Colin Macilwain assesses whether this is likely to revive its share price.

A technique for turning genes off has sparked a flurry of biotech investment. Erika Check investigates.

For big oil companies, carbon dioxide is waste; for people who grow fruit, it's a valuable commodity. Ned Stafford reports on a marriage of convenience in the Netherlands.